X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 4c; Cash and Cash Equivalents of $77.7M

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q3 EPS of ($0.76), $0.04 worse than the analyst estimate of ($0.72).

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold
• Lumentum shares rise on analyst upgrades, AI demand outlook